Author: admin

Growth Mindsets Begin at Young Scholars Academy

When was the last time you heard that it’s okay to fail? At Young Scholars Academy, we are creating a movement of young scholars who are more focused on process rather than outcome. While nobody likes failure or rejection, we’ve learned that success–more often than not–lies on the other side of those setbacks. Our future generation needs to be encouraged to learn and explore without fear. This is the essence of the Growth Mindset.

OUR MISSION

Using our proud traditions and diverse community, Young Scholars Academy prepares all students to become creative, ethical, and critical thinkers for lifelong success in a global society.

OUR VISION

Instilling Academic Success and Resiliency in ALL Scholars

  • Every scholar will become his or her best ethical and intellectual self.

  • Every educator will inspire students to strive for academic excellence and strength of character.

  • Every scholar will persevere to reach his or her highest social, emotional, and academic potential.

  • Every educator will leverage failure and mistakes as opportunities for the scholars to learn and grow.

  • Every educator’s objective is to make the process of learning fun and exciting again.

  • Every classroom will develop engaging and professional learning communities to support the Growth Mindset.


OUR BELIEFS

We believe…

  • A culture of caring is essential for reaching one’s full potential.

  • Respect for oneself and others is fundamentally necessary to building self-worth and dignity.

  • Taking responsibility for one’s actions enables scholars to thrive during challenges.

  • A safe environment establishes a sense of security, which allows scholars to take chances on new ideas.

  • Strong character sets the framework for good citizenship and social development.

  • Every scholar deserves the opportunity to develop his or her potential to learn and grow.

  • Intelligence is developed through attitude, effort, and perseverance.

  • Mistakes are viewed as opportunities to learn and grow, not as failure or a disappointment.

Are you ready for your child to have access to exceptional education? Schedule your tour today! Visit ysabr.com.

Media Contact
Company Name: Young Scholars Academy
Contact Person: Megan Garretson
Email: Send Email
Country: United States
Website: https://ysabr.com/

Authors Dr. Jayne Gardner and Joel Patterson Announce Launch of Best Job Ever on October 25, 2024

Dallas, Texas, USA – October 25, 2024 – Prepare to transform your workplace culture! Dr. Jayne Gardner and Joel Patterson are thrilled to announce the launch of their groundbreaking book, Best Job Ever: How a Culture of Coaching Can Transform Your Company, set to hit the shelves on October 25, 2024. This must-read title is already generating buzz as it proudly holds a perfect 5.0 rating and is the #1 New Release in Knowledge Capital on Amazon.

Best Job Ever serves as a vital algorithm for leaders who recognize the power of investing in their people. The authors challenge the conventional profit-centric business models by advocating for a new paradigm where happier employees lead to higher profits. This enlightening book explores the critical importance of emotional intelligence, self-awareness, and resilience in the workplace—essential soft skills that not only benefit individuals but are also crucial drivers of organizational success.

“In today’s competitive landscape, organizations must evolve from traditional management styles to a coaching culture that prioritizes employee well-being,” says Dr. Gardner. “Our book outlines practical strategies that empower leaders to foster a supportive environment, resulting in both personal and organizational growth.”

Joel Patterson, a renowned Forbes Book Author known for The Big Commitment, adds, “We believe that when leaders commit to developing their teams through coaching, they unlock potential that translates into greater innovation and profitability. This book is a call to action for all leaders who aspire to create the best job ever for their employees.”

Join the movement towards a better workplace! Readers are encouraged to purchase Best Job Ever on Amazon and help it achieve Best Seller status. Your support not only champions a revolutionary approach to workplace culture but also invests in the well-being of your teams.

About the Authors

Dr. Jayne Gardner is an acclaimed expert in organizational behavior, with years of experience helping businesses enhance their culture and productivity. Jayne is the inventor of the “High Performance Breakthrough” course, designed to foster a new culture of people empowerment and personal growth.

Joel Patterson is the Founder of The Vested Group, a Technology Services Provider focused on the licensing, implementation, and support of a modern cloud-based ERP, CRM & eCommerce solution for growing companies called Oracle+Netsuite. He has over twenty years of experience in the consulting industry.

For more information about Best Job Ever, to schedule interviews, or to request review copies, please contact Wilene Dunn, wilene@wcdenterprises.com.

Media Contact
Company Name: WCD Enterprises
Contact Person: Wilene Dunn
Email: Send Email
Phone: 713-518-4914
Country: United States
Website: https://wcdenterprises.com

Louisiana Key Academy’s New Baton Rouge Campus: Focus on Developing the Whole Child

Louisiana Key Academy (LKA) has long been a beacon of hope for families with dyslexia, offering tailored educational experiences designed to help students thrive academically and personally. As part of its unwavering commitment to the development of the whole child. This year the campus has moved to a larger facility that marks a pivotal moment for LKA as it enhances both its capacity and its academic offerings to better serve the needs of the Baton Rouge community and nearby Ascension and Livingston Parishes.

The larger classrooms and athletic areas, coupled with sprawling outdoor spaces, offer an environment where students can engage in physical, social, and emotional growth alongside academic learning. This holistic approach is at the core of LKA’s mission: to empower students not just with academic knowledge but with the skills they need to succeed in all areas of life.

According to Monica Owens, principal of LKA Baton Rouge, the school’s commitment to fostering the “whole child” remains central to its educational philosophy. “We are thrilled to open our new campus and introduce programs that foster not only academic excellence but also personal growth,” she said. The new facilities include a full-size basketball gymnasium for hosting home games and physical education classes, a theater for school productions, and expansive fields that will support various athletic activities such as flag football and soccer. In addition to physical wellness, the expanded campus supports innovative academic programming that places equal emphasis on intellectual development.

LKA Baton Rouge has strengthened its STEM (Science, Technology, Engineering, and Mathematics) and reading programs, which are central to helping students with dyslexia succeed. The school’s individualized instruction and commitment to using the latest educational techniques ensure that students are not only keeping pace with their peers but excelling in subjects that are critical for future success

The enhanced academic offerings currently support students from Kindergarten through Grade 10, with plans to extend through Grades 11 and 12 over the next two years. This expansion reflects LKA’s long-term vision of supporting students throughout their entire educational journey, preparing them for both higher education and the broader world beyond.

Louisiana Key Academy Baton Rouge continues to be a leader in providing a nurturing, inclusive, and innovative environment where students with dyslexia can unlock their potential. For more information about enrollment and the new campus, visit www.lkaschools.com.

Media Contact
Company Name: Louisiana Key Academy
Contact Person: Nicole Ruccolo
Email: Send Email
Country: United States
Website: https://www.lkaschools.com/

Woman’s Hospital: Healing and Empowering Mothers Who Experience Depression During and After Pregnancy

For the first time ever in Louisiana, there is now a safe place where women who experience depression either during or after pregnancy can receive inpatient treatment, and it is located at Woman’s Hospital in Baton Rouge. “Our mission is to improve the lives of women and infants, and it is fitting that this unit is located on our campus,” said Dr. Kelly Cannon, director of inpatient perinatal psychiatry. The only one of its kind in the state, Woman’s Perinatal Mental Health Unit (PMHU) opened this September and serves as a beacon of hope for women across Louisiana and the southern region. “It is so gratifying to hear from patients and their families about what a difference this service is making in their lives. Women often suffer in silence because what they are dealing with can feel very isolating, but the truth is they are not alone, and they don’t have to push through by themselves. In the few short months that we have been open, I can tell you that mothers are indeed getting the help they need,” said Cannon.

Feelings of sadness and depression among women during this time is very common. Approximately one in five women will experience mental health conditions either during or after pregnancy. Most go undiagnosed and untreated, but research shows the majority of women respond positively once diagnosed and treated, which is why it is important not to ignore the symptoms. “There is no need to feel ashamed. The treatment options are effective and tailored to fit each patient’s needs. We are here to empower women,” said Cannon.

Some of the symptoms include extreme sadness that lasts for weeks and months, difficulty sleeping, depression, panic attacks, stress, and postpartum psychosis. Woman’s PMHU provides individualized treatment with both psychiatric and recreational therapies. The care teams include a psychiatrist, registered nurses dually trained in obstetrics and psychiatry, therapists, social workers, mental health technicians, and lactation consultants. The unit is also supported by onsite OB/GYNs and maternal-fetal medicine specialists.

The PMHU is unique in that infant visitation is encouraged to help with bonding and healing, and a woman can be admitted at any time during her pregnancy or up to one year afterwards. In addition, each patient has her own private bedroom and bath, and only 10 patients can stay in the unit at any one time to ensure personalized attention.

The comprehensive care does not end when a patient leaves. Appropriate follow-up appointments are scheduled, and community resources are provided to ensure their road to recovery is successful.

“Caring for mothers and their families is what we do every day,” said Cannon. “The main thing to remember is that mental health conditions are common during the perinatal period. In fact, there is an increased risk during this time. However, when properly diagnosed it is treatable, and we can help women become the mothers they always wanted to be.”

For more information visit: Womans.org/PMHU

Media Contact
Company Name: Woman’s Hospital
Contact Person: Margaret Temple
Email: Send Email
Country: United States
Website: https://www.womans.org/inpatient-behavioral-health-care

Local SEO in Florida: ilocal SEO Launches its Dedicated Multi-Channel Social Network to Boosts Business Visibility

Local SEO in Florida: ilocal SEO Launches its Dedicated Multi-Channel Social Network to Boosts Business Visibility
ilocal SEO boosts Florida businesses with affordable SEO services, offering backlinks and social media exposure to over 45,000 users through its FloridaBeaches.io platform.

With the unveiling of its offering for affordable local SEO in Florida, ilocal SEO has carved a niche in the digital marketing landscape, providing a powerful combination of social media reach and a regional focus to help small and medium-sized businesses (SMBs) boost their search engine rankings and attract more local customers. Through its robust network and specialized services, the agency ensures businesses increase their reach by listing on its highly-ranked platform, FloridaBeaches.io. 

The Florida Beaches website is a cornerstone of the agency’s strategy for boosting brand visibility and search engine performance for businesses in Florida. ilocal SEO provides SMBs with an affordable and effective way to enhance their online presence and offers an SEO boost from a high-quality backlink from a reputable regional website. The website has already ranked Miracle Leaf Clematis for brand-related searches through its strategic use of business listings, demonstrating the effectiveness of its SEO model.

FloridaBeaches.io is the only network in Florida that distributes listings to over 45,000 users across its social media channels. This network includes platforms like Facebook, Instagram, and Reddit that drive traffic back to the listed businesses. By leveraging social signals from this diverse audience base, the platform increases brand awareness and enhances the visibility of listings in search engine results pages (SERPs).

The demand for Local SEO in Florida is increasing as more businesses recognize the importance of ranking well in local search results. To remain competitive, SMBs that serve regional customers need strong visibility in local searches. ilocal SEO understands this need and focuses on helping businesses achieve top rankings for geo-specific keywords, ensuring their brands reach out to potential customers searching for services in Florida.

For more information, visit https://floridabeaches.io

Many small businesses find the high service fees of SEO and digital marketing a restrictive barrier to entry. Conversely, one of ilocal SEO’s strengths is its highly cost-effective solution for SMBs looking to improve their online presence. 

What makes ilocal SEO stand out from competitors is its ability to offer more than just a local listing. Businesses that list on FloridaBeaches.io gain a backlink and benefit from social media exposure to a captive Florida-based audience. The platform delivers a targeted social media blast to thousands of users, helping businesses build credibility, attract engagement, and draw more website traffic.

For businesses looking to dominate local search in Florida, this platform offers a simple, affordable, and highly effective way to gain traction online. The service helps companies rank higher on Google for local search terms, ensuring a competitive edge with a direct link to a high-traffic website relevant to their region and industry.

Expertise in utilizing social networks is a key success factor for ilocal SEO in increasing the online visibility of SMBs and improving brand-related search performance, creating a dual advantage for businesses looking to build their online presence. It is the only local SEO network distributing such a link to a broad social media base. 

By distributing business listings to a vast audience through social media channels, the agency ensures businesses listed on FloridaBeaches.io gain significant brand awareness, social signals, and a backlink from a reputable website in Florida, resulting in a surge of social signals essential for improving search engine rankings. 

ilocal SEO is a game-changer for SMBs in Florida that need to improve their visibility in local searches. With its innovative platform, the agency provides affordable listing services with a regional backlink from FloridaBeaches.io, complemented by comprehensive social media promotion that maximizes the value of each listing, all at a fraction of what other agencies charge. By leveraging a powerful social media network and a reputable regional website, ilocal SEO stands out as a top choice for businesses looking to grow their online presence through the Florida Beaches.

About the Agency:

ilocal SEO is a Florida-based digital marketing agency specializing in local SEO for small and medium-sized businesses (SMBs). The agency operates FloridaBeaches.io as a platform to enhance business visibility through high-quality backlinks and targeted social media exposure. By distributing business listings to over 45,000 users across multiple social channels, ilocal SEO helps businesses gain brand awareness, social signals, and improved search engine rankings. Known for offering cost-effective solutions, ilocal SEO provides SMBs with an affordable way to boost their online presence and reach local customers, making it a top choice for businesses looking to improve their local SEO in Florida.

Media Contact
Company Name: Ilocal SEO
Contact Person: Lenny Mauricio
Email: Send Email
Phone: 5612816777
State: Florida
Country: United States
Website: https://floridabeaches.io

Silverado Tesla Screen Product Launch Pushes Automotive Technology Boundaries

Silverado Tesla Screen Product Launch Pushes Automotive Technology Boundaries
Pompano Beach-based RDVFL has launched the GM-SCREEN-1923S, a 15.6-inch Tesla-style screen engineered for easy installation and superior performance. The product boasts a sleek design that integrates effortlessly with the interior of the Chevy Silverado and GMC Sierra.

RDVFL and company owner Rich De Sclafani are pleased to announce the launch of the 15.6-inch Vertical Touchscreen—a high-definition, capacitive touchscreen that delivers a crystal-clear display and responsive user experience. 

The Silverado Tesla Screen retains all the factory settings and is compatible with the 2019-2023 Chevrolet Silverado with a 7″ or 8″ OEM Screen or the 2019-2023 GMC Sierra with a 7″ or 8″ OEM Screen. The product includes digital A/C controls and allows users to watch Netflix or any available downloaded video streaming app. The upgrade is for the screen and does not replace the OEM radio, which stays intact and can be used through the RDVFL screen. The Chevy Silverado / GM Sierra Screen Upgrade works with BOSE and non-BOSE systems. 

Led by company owner Rich De Sclafani, RDVFL’s success is driven by a team passionate about pushing the boundaries of automotive technology. With over 27 years of experience and expertise in the 12-volt industry, De Sclafani’s insights into the market allow the team to anticipate market trends and deliver solutions that exceed expectations.

“We are a US-based, family-owned company headquartered in Pompano Beach, Florida, specializing and offering the highest quality Tesla screens for Chevy Silverado and GMC Sierra and we stand 100% behind our products, making us the go-to specialist company for this type of integration products in the market,” said De Sclafani. “We are the only company that offers GMC Sierra and Chevy Silverado Screen Upgrades and a 3-year warranty backed by US-support. When you call us, we pick up the phone, unlike purchasing through Amazon where customer support is non-existent.”

Additional information about the company is available at https://rdvfl.com/

Chevy Silverado and GMC Sierra vehicle owners looking to upgrade their in-car screens appreciate the Wireless Apple CarPlay and Android Auto. The unit is equipped with wireless connectivity, allowing drivers to seamlessly connect their smartphones for access to music, apps, navigation, and hands-free communication without the hassle of cables. A full list of specs and applicable images of the installed upgrade are available on the company website. These specifications include front and rear camera input and full touchscreen control. The unit supports an OEM 360 camera, steering wheel controls, and full HD video format with a 1440 x 1920 capacitive multi-touch screen and split screen function.

The GM-SCREEN-1923S includes digital A/C controls, built-in WiFi, and built-in Google Play Store Access. Users can access YouTube, Netflix, Sling, Disney, Amazon Prime Video and more. Built-in GPS with both online and offline maps supported adds navigational help.

Additional features of the RDVFL GM-SCREEN-1923S 15.6-inch Tesla-style screen include a fully plug-and-play installation designed for simplicity. There is no required complex wiring or modifications—just an easy, straightforward installation process. RDVFL backs this product with a comprehensive three-year warranty, ensuring peace of mind and customer satisfaction. Advanced features include navigation, vehicle diagnostics, multimedia control, and more, all accessible through the intuitive touchscreen interface.

Rich De Sclafani and his two daughters work together and provide all support and shipping from the South Florida location. The firm’s goal is to provide the best support, CarPlay Interfaces, Wireless CarPlay Adapters, backup camera interfaces, and other 12-volt electronics available through the network of authorized distributors and dealers across North and South America. RDVFL only offers the highest quality products that the company guarantees and stands behind 100%, making it the go-to 12-volt company for the type of car integration products handled by the firm. 

About RDVFL: 

Rich De Sclafani has over 27 years of experience in the industry. For the last 15+ years, he has held positions in the top companies in the OEM Integration category. RDVFL is proud to be a member of the MEA and a supporter of the MECP program.

Media Contact
Company Name: RDVFL
Contact Person: Rich De Sclafani
Email: Send Email
Phone: (561) 922-7747
Address:2745 NW 19th St
City: Pompano Beach
State: FL
Country: United States
Website: https://rdvfl.com/

Mary Drucker: Vice President at Audax Private Debt, Leading the Senior Debt Investment Team

Mary Drucker: Vice President at Audax Private Debt, Leading the Senior Debt Investment Team

Mary Drucker
Mary Drucker, a seasoned financial professional, serves as Vice President at Audax Private Debt, where she plays a pivotal role in the senior debt investment team.

Since joining Audax in 2017, Mary has contributed to the firm’s growth and success by leveraging her expertise in debt financing. Before Audax, Mary worked as an Associate Analyst at Moody’s Investors Service, where she honed her skills in financial analysis and risk assessment.

Mary Drucker holds a Bachelor of Arts in Economics from Lafayette College, demonstrating a solid foundation in financial principles that has propelled her career forward in the investment industry. Her strategic leadership and financial acumen make her a valuable asset at Audax Private Debt.

In addition to Mary Drucker, other prominent individuals in the finance world share her name. Mary Ann Drucker, for example, is a financial services advisory professional who assists with portfolio management and trading. She holds an MBA from George Washington University and dual bachelor’s degrees in finance and economics from the University of Maryland.

About Mary Drucker 

Mary Drucker currently serves as a Vice President at Audax Private Debt, where she is an integral member of the senior debt investment team. Since joining the company in 2017, she has significantly shaped Audax’s investment strategies and managed key financial projects. Before her work at Audax, Mary was an associate analyst at Moody’s Investors Service, where she gained valuable experience in economic analysis and risk assessment.

Mary holds a Bachelor of Arts in Economics from Lafayette College, which has equipped her with a strong foundation in economic principles and investment strategies. In her free time, she loves to travel and visit her favorite destinations, such as Palm Beach, FL. 

About Audax Private Debt

Audax Private Debt is a leading provider of debt financing solutions for North American middle-market companies. Established in 2000, Audax offers flexible capital solutions, including first lien, second lien, unitranche, subordinated debt, and equity co-investments. With a strong focus on partnering with established companies, Audax provides financial support to help businesses grow through leveraged buyouts, acquisitions, and other strategic initiatives. The firm’s expertise has positioned it as a trusted partner for middle-market companies seeking growth and value creation. 

Media Contact
Contact Person: Mary Drucker
Email: Send Email
Country: United States
Website: https://media.licdn.com/dms/image/v2/C4E03AQHQqZH_L4w-kA/profile-displayphoto-shrink_200_200/profile-displayphoto-shrink_200_200/0/1517257807177?e=2147483647&v=beta&t=l6gDqQIG8Op2_FJa5D19TjndPi08LQq5HDJ1gf9cFsk

Cabinet IQ Unveils Exclusive Custom Kitchen Cabinet Collection in Cedar Park, Featuring Innovative Designs and Premium Materials

Cabinet IQ Unveils Exclusive Custom Kitchen Cabinet Collection in Cedar Park, Featuring Innovative Designs and Premium Materials

A recent complete kitchen remodel in Cedar Park, Texas with custom cabinetry, quartz countertops, lighting and accessories
Cabinet IQ launches its exclusive custom kitchen cabinet collection in Cedar Park, Texas, offering homeowners a range of innovative designs and premium materials. The collection combines functionality, style, and durability, providing the perfect solutions for modern kitchen remodels.

Cedar Park, Texas – Oct 25, 2024 – Cabinet IQ, a leader in kitchen and bathroom remodeling, proudly announces the launch of its exclusive custom kitchen cabinet collection in Cedar Park, Texas. This new collection offers homeowners a wide variety of innovative designs, premium materials, and fully customizable options, setting a new standard for quality and style in kitchen remodeling.

The exclusive collection includes:

Innovative Designs: The new cabinet collection features a range of styles, from contemporary and sleek to classic and traditional, ensuring options for every taste and preference.

Premium Materials: Cabinet IQ sources the highest quality materials, including hardwood, eco-friendly composites, and durable finishes, to create cabinets that are both beautiful and long-lasting.

Customizable Solutions: Each cabinet is fully customizable, allowing homeowners to choose from various sizes, colors, finishes, and hardware options to create the perfect fit for their kitchen space.

“At Cabinet IQ Cedar Park, we understand that the kitchen is the heart of the home, and our exclusive collection of custom cabinets is designed to enhance both the functionality and aesthetic appeal of any kitchen,” said Michael Hartel, owner of Cabinet IQ Cedar Park. “We are committed to providing high-quality, personalized solutions that reflect our clients’ unique style and needs.”

In addition to custom kitchen cabinets, Cabinet IQ Cedar Park offers comprehensive kitchen remodeling services, including countertop installations and complete kitchen transformations. The team works closely with homeowners from the initial consultation through to the final installation, ensuring a seamless and stress-free renovation process.

The Cedar Park location is ready to serve homeowners in Cedar Park, Leander, and the surrounding communities, offering expert design consultations to help clients create their ideal kitchen. Whether you’re looking for a modern, minimalistic look or a more traditional style, Cabinet IQ’s new collection provides the versatility and craftsmanship needed to achieve your dream kitchen.

For more information about Cabinet IQ Cedar Park and their exclusive custom kitchen cabinet collection, visit their website at https://maps.app.goo.gl/xEWv1ubFezeR7xnD7 or contact Michael Hartel at 254-318-3528.

About Cabinet IQ:

Cabinet IQ is a premier kitchen and bathroom remodeling company specializing in high-quality cabinetry and countertops. With a commitment to innovation and customer satisfaction, Cabinet IQ continues to set the standard for home renovation excellence.

Media Contact
Company Name: Cabinet IQ
Contact Person: Michael Hartel
Email: Send Email
Phone: 254-318-3528
Address:2419 S Bell Blvd
City: Cedar Park
State: Texas 78613
Country: United States
Website: https://maps.app.goo.gl/xEWv1ubFezeR7xnD7

Triple Negative Breast Cancer Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | ModernaTX, Inc., OncoTherapy Science, Phoenix Molecular

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Triple Negative Breast Cancer pipeline constitutes 75+ key companies continuously working towards developing 80+ Triple Negative Breast Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Triple Negative Breast Cancer Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Triple Negative Breast Cancer Market.

 

The Triple Negative Breast Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Triple Negative Breast Cancer Pipeline Report: 

  • Companies across the globe are diligently working toward developing novel Triple Negative Breast Cancer treatment therapies with a considerable amount of success over the years. 

  • Triple Negative Breast Cancer companies working in the treatment market are Sichuan Kelun-Biotech Biopharmaceutical, Akeso Biopharma, ProLynx, ModernaTX, Inc., OncoTherapy Science, Phoenix Molecular Designs, Abbisko Therapeutics, BioLite, Inc., Zenith Epigenetics, HiberCell, Inc., Infinity Pharmaceuticals, G1 Therapeutics, Inc, Jiangsu HengRui Medicine Co., Ltd, Shanghai Henlius Biotech, and others, are developing therapies for the Triple Negative Breast Cancer treatment 

  • Emerging Triple Negative Breast Cancer therapies in the different phases of clinical trials are- SKB264, AK117, PLX038, mRNA-2752, OTS167PO, PMD-026, X4P-001, BLEX 404, ZEN003694 +Talazoparib, mprime PGG, IPI-549, Trilaciclib, Camrelizumab, HLX10, and others are expected to have a significant impact on the Triple Negative Breast Cancer market in the coming years. 

  • In February 2024, Trodelvy (sacituzumab govitecan-hziy) is the first approved antibody-drug conjugate for treating advanced triple-negative breast cancer (TNBC) in adults who have undergone at least two prior treatments for metastatic disease. It is also indicated for pre-treated HR+/HER2- metastatic breast cancer patients and second-line metastatic TNBC patients who have received endocrine-based therapy and at least two other systemic therapies.

  • In June 2023, Gilead Sciences awarded the first “Toward Health Equity for Black People Impacted by Triple Negative Breast Cancer Resource Hub” grant to TOUCH, The Black Breast Cancer Alliance, in partnership with the Triple Negative Breast Cancer Foundation, the American Association for Cancer Research (AACR), and Nueva Vida for their project Black TNBC Matters.

  • In May 2023, The supplemental new drug application (“sNDA”) for Shanghai Junshi Biosciences Co., Ltd.’s anti-PD-1 monoclonal antibody, toripalimab, has been accepted by the National Medical Products Administration. The drug is intended to be used in conjunction with albumin-bound paclitaxel to treat PD-L1 positive (CPS ≥ 1) untreated metastatic or recurrent metastatic triple-negative breast cancer.

  • In May 2023, The announcement was made by Eisai Co., Ltd. and Bliss Biopharmaceutical (Hangzhou) Co., Ltd. on the cooperative development agreement for BB-1701, an antibody-drug conjugate (ADC) with option rights for strategic partnership. In compliance with the terms of the joint development agreement, Eisai will carry out a Phase II clinical trial for breast cancer, pay BlissBio upfront and development milestones, and acquire the option rights to develop and market BB-1701 internationally, with the exception of Greater China (China, Hong Kong, Macau, Taiwan).

  • In May 2023, AML and breast cancer will be treated with gamma-delta T cells (gdTc) thanks to a research collaboration agreement CytoMed Therapeutics Limited signed with The University of Texas MD Anderson Cancer Center (“MD Anderson”) in Houston, Texas. The goal of this partnership is to provide patients with breast cancer and AML with novel, reasonably priced therapy options that address their unmet requirements.

  • In March 2023, The outcomes of the phase II umbrella study FUTURE, which looked at whether the subtyping-based approach may help patients with metastatic TNBC, were revealed. Enrolled in seven parallel arms were 141 patients with a median of three prior lines of therapy in the metastatic scenario.

 

Triple Negative Breast Cancer Overview

Triple Negative Breast Cancer (TNBC) is characterized by a tumor that has negative levels of estrogen and progesterone (ER/PR), as determined by immunohistochemistry (IHC), and neither immunohistochemistry (IHC) nor fluorescence in situ hybridization (FISH) has detected overexpression of the HER2 gene.

 

Get a Free Sample PDF Report to know more about Triple Negative Breast Cancer Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/triple-negative-breast-cancer-tnbc-pipeline-insight

 

Emerging Triple Negative Breast Cancer Drugs Under Different Phases of Clinical Development Include:

  • SKB264: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

  • AK117: Akeso Biopharma

  • PLX038: ProLynx

  • mRNA-2752: ModernaTX, Inc.

  • OTS167PO: OncoTherapy Science

  • PMD-026: Phoenix Molecular Designs

  • X4P-001: Abbisko Therapeutics

  • BLEX 404: BioLite, Inc.

  • ZEN003694 +Talazoparib: Zenith Epigenetics

  • mprime PGG: HiberCell, Inc.

  • IPI-549: Infinity Pharmaceuticals

  • Trilaciclib: G1 Therapeutics, Inc

  • Camrelizumab: Jiangsu HengRui Medicine Co., Ltd

  • HLX10: Shanghai Henlius Biotech

 

Triple Negative Breast Cancer Route of Administration

Triple Negative Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral

  • Parenteral

  • Intravenous

  • Subcutaneous

  • Topical

 

Triple Negative Breast Cancer Molecule Type

Triple Negative Breast Cancer Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy 

 

Triple Negative Breast Cancer Pipeline Therapeutics Assessment

  • Triple Negative Breast Cancer Assessment by Product Type

  • Triple Negative Breast Cancer By Stage and Product Type

  • Triple Negative Breast Cancer Assessment by Route of Administration

  • Triple Negative Breast Cancer By Stage and Route of Administration

  • Triple Negative Breast Cancer Assessment by Molecule Type

  • Triple Negative Breast Cancer by Stage and Molecule Type

 

DelveInsight’s Triple Negative Breast Cancer Report covers around 80+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I)

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

 

Further Triple Negative Breast Cancer product details are provided in the report. Download the Triple Negative Breast Cancer pipeline report to learn more about the emerging Triple Negative Breast Cancer therapies

 

Some of the key companies in the Triple Negative Breast Cancer Therapeutics Market include:

Key companies developing therapies for Triple Negative Breast Cancer are – ModernaTX, Inc, NuGenerex Immuno-Oncology, Pfizer, Jiangsu Alphamab Biopharmaceuticals Co., Ltd., BioLite, Inc., ImmunityBio, Inc., PharmAbcine, Genexine, Inc.,  CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Novartis Pharmaceuticals, Klus Pharma, Ayala Pharmaceuticals, Inc, Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., Infinity Pharmaceuticals, HiberCell, Inc., Zenith Epigenetics, BioLite, Inc., Abbisko Therapeutics, Phoenix Molecular Designs, OncoTherapy Science, Akeso Biopharma, Chipscreen Biosciences, OncoPep, Inc., Iovance Biotherapeutics, Inc., SynDevRx, Inc., Hoffmann-La Roche, Celcuity, Inc., Amgen, AstraZeneca, NBE-Therapeutics AG, Fusion Pharmaceuticals, Immutep Limited, and others.

 

Triple Negative Breast Cancer Pipeline Analysis:

The Triple Negative Breast Cancer pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Triple Negative Breast Cancer with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Triple Negative Breast Cancer Treatment.

  • Triple Negative Breast Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Triple Negative Breast Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Triple Negative Breast Cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Triple Negative Breast Cancer drugs and therapies

 

Triple Negative Breast Cancer Pipeline Market Drivers

  • Increase in the prevalence of Triple Negative Breast Cancer, increasing Research and Development activities are some of the important factors that are fueling the Triple Negative Breast Cancer Market.

 

Triple Negative Breast Cancer Pipeline Market Barriers

  • However, high cost of the treatment, side effects associated with the treatment and other factors are creating obstacles in the Triple Negative Breast Cancer Market growth.

 

Scope of Triple Negative Breast Cancer Pipeline Drug Insight    

  • Coverage: Global

  • Key Triple Negative Breast Cancer Companies: Sichuan Kelun-Biotech Biopharmaceutical, Akeso Biopharma, ProLynx, ModernaTX, Inc., OncoTherapy Science, Phoenix Molecular Designs, Abbisko Therapeutics, BioLite, Inc., Zenith Epigenetics, HiberCell, Inc., Infinity Pharmaceuticals, G1 Therapeutics, Inc, Jiangsu HengRui Medicine Co., Ltd, Shanghai Henlius Biotech, and others

  • Key Triple Negative Breast Cancer Therapies: SKB264, AK117, PLX038, mRNA-2752, OTS167PO, PMD-026, X4P-001, BLEX 404, ZEN003694 +Talazoparib, mprime PGG, IPI-549, Trilaciclib, Camrelizumab, HLX10, and others

  • Triple Negative Breast Cancer Therapeutic Assessment: Triple Negative Breast Cancer current marketed and Triple Negative Breast Cancer emerging therapies

  • Triple Negative Breast Cancer Market Dynamics: Triple Negative Breast Cancer market drivers and Triple Negative Breast Cancer market barriers 

 

Request for Sample PDF Report for Triple Negative Breast Cancer Pipeline Assessment and clinical trials

 

Table of Contents

1. Triple Negative Breast Cancer Report Introduction

2. Triple Negative Breast Cancer Executive Summary

3. Triple Negative Breast Cancer Overview

4. Triple Negative Breast Cancer- Analytical Perspective In-depth Commercial Assessment

5. Triple Negative Breast Cancer Pipeline Therapeutics

6. Triple Negative Breast Cancer Late Stage Products (Phase II/III)

7. Triple Negative Breast Cancer Mid Stage Products (Phase II)

8. Triple Negative Breast Cancer Early Stage Products (Phase I)

9. Triple Negative Breast Cancer Preclinical Stage Products

10. Triple Negative Breast Cancer Therapeutics Assessment

11. Triple Negative Breast Cancer Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Triple Negative Breast Cancer Key Companies

14. Triple Negative Breast Cancer Key Products

15. Triple Negative Breast Cancer Unmet Needs

16 . Triple Negative Breast Cancer Market Drivers and Barriers

17. Triple Negative Breast Cancer Future Perspectives and Conclusion

18. Triple Negative Breast Cancer Analyst Views

19. Appendix

20. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Triple Negative Breast Cancer Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | ModernaTX, Inc., OncoTherapy Science, Phoenix Molecular

Metastatic HER2-positive Breast Cancer Market Expected to Experience Major Growth by 2034, According to DelveInsight | Ambrx, Zymeworks/Jazz Pharma, Roche, Criterium, Seagen, Sichuan Baili Pharma,

The Key Metastatic HER2-positive Breast Cancer Companies in the market include – Daiichi Sankyo/AstraZeneca, Roche/Chugai, Seagen, MacroGenics, Ambrx, Zymeworks/Jazz Pharmaceuticals, Taiho Oncology, GeneQuantum Healthcare, Criterium, Inc., Seagen Inc., Sichuan Baili Pharma, BioInvent International AB, and others.

DelveInsight’s “Metastatic HER2-positive Breast Cancer Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Metastatic HER2-positive Breast Cancer, historical and forecasted epidemiology as well as the Metastatic HER2-positive Breast Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Metastatic HER2-positive Breast Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Metastatic HER2-positive Breast Cancer Market Forecast

 

Some of the key facts of the Metastatic HER2-positive Breast Cancer Market Report: 

  • The Metastatic HER2-positive Breast Cancer market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

  • In January 2024, Processa Pharmaceuticals revealed its intentions to broaden the scope of Next Generation Capecitabine (NGC-Cap) development by including its application in the treatment of advanced or metastatic breast cancer, starting with the forthcoming Phase II trial. NGC-Cap involves the concurrent administration of PCS6422 and low doses of Capecitabine. The company aims to commence the Phase II study in the third quarter of 2024.

  • Anti-HER2 therapies, including HERCEPTIN, PERJETA, KADCYLA, and ENHERTU, have transformed the treatment landscape for HER2-positive cancers, which were once linked to more aggressive disease and worse prognoses.

  • Seagen’s extensive TUKYSA development strategy encompasses a Phase II trial (HER2CLIMB-04) that combines TUKYSA with ENHERTU for second-line treatment of HER2-positive breast cancer, as well as a Phase III trial (HER2CLIMB-05) assessing TUKYSA in combination with HERCEPTIN and Roche’s PERJETA as a first-line maintenance therapy.

  • Estimates indicate that the total number of new HER2-positive breast cancer cases in the seven major markets reached approximately 102,000 in 2023. This figure is anticipated to rise throughout the forecast period from 2024 to 2034.

  • The highest number of HR+/HER2+ breast cancer cases was found in the United States, with approximately 32,000 cases reported.

  • Germany recorded the highest number of HER2-positive breast cancer cases among the EU4 and the UK, with approximately 11,000 cases in 2023, whereas Spain had the fewest cases.

  • In Japan, Stage II had the highest number of HER2-positive breast cancer cases, with approximately 6,000 cases reported in 2023.

  • Key Metastatic HER2-positive Breast Cancer Companies: Daiichi Sankyo/AstraZeneca, Roche/Chugai, Seagen, MacroGenics, Ambrx, Zymeworks/Jazz Pharmaceuticals, Taiho Oncology, GeneQuantum Healthcare, Criterium, Inc., Seagen Inc., Sichuan Baili Pharma, BioInvent International AB, and others

  • Key Metastatic HER2-positive Breast Cancer Therapies: ENHERTU (fam-trastuzumab deruxtecan-nxk), KADCYLA (ado-trastuzumab emtansine), HERCEPTIN HYLECTA, TUKYSA, MARGENZA, ARX788, Zanidatamab, TAS2940, GQ1001, Giredestrant, Alpelisib, Tucatinib, BL-M07D1, BI-1607, and others 

  • The Metastatic HER2-positive Breast Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Metastatic HER2-positive Breast Cancer pipeline products will significantly revolutionize the Metastatic HER2-positive Breast Cancer market dynamics.

 

Metastatic HER2-positive Breast Cancer Overview

Metastatic HER2-positive breast cancer refers to breast cancer that has spread beyond the breast and nearby lymph nodes to other parts of the body, such as the bones, liver, lungs, or brain, and is characterized by the overexpression of the human epidermal growth factor receptor 2 (HER2) protein. HER2-positive breast cancer tends to be more aggressive than other types of breast cancer.

 

Get a Free sample for the Metastatic HER2-positive Breast Cancer Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/metastatic-her2-positive-breast-cancer-market 

 

Metastatic HER2-positive Breast Cancer Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Metastatic HER2-positive Breast Cancer Epidemiology Segmentation:

The Metastatic HER2-positive Breast Cancer market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Metastatic HER2-positive Breast Cancer

  • Prevalent Cases of Metastatic HER2-positive Breast Cancer by severity

  • Gender-specific Prevalence of Metastatic HER2-positive Breast Cancer

  • Diagnosed Cases of Episodic and Chronic Metastatic HER2-positive Breast Cancer

 

Download the report to understand which factors are driving Metastatic HER2-positive Breast Cancer epidemiology trends @ Metastatic HER2-positive Breast Cancer Epidemiology Forecast

 

Metastatic HER2-positive Breast Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Metastatic HER2-positive Breast Cancer market or expected to get launched during the study period. The analysis covers Metastatic HER2-positive Breast Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Metastatic HER2-positive Breast Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Metastatic HER2-positive Breast Cancer Therapies and Key Companies

  • ENHERTU (fam-trastuzumab deruxtecan-nxk): Daiichi Sankyo/AstraZeneca

  • KADCYLA (ado-trastuzumab emtansine): Roche/Chugai

  • HERCEPTIN HYLECTA: Roche

  • TUKYSA: Seagen

  • MARGENZA: MacroGenics

  • ARX788: Ambrx

  • Zanidatamab: Zymeworks/Jazz Pharmaceuticals

  • TAS2940: Taiho Oncology

  • GQ1001: GeneQuantum Healthcare

  • Giredestrant: Roche

  • Alpelisib: Criterium, Inc.

  • Tucatinib: Seagen Inc.

  • BL-M07D1: Sichuan Baili Pharma

  • BI-1607: BioInvent International AB

 

Discover more about therapies set to grab major Metastatic HER2-positive Breast Cancer market share @ Metastatic HER2-positive Breast Cancer Treatment Landscape 

 

Metastatic HER2-positive Breast Cancer Market Drivers

  • Strong uptake of Daiichi/Astra’s ENHERTU in second and third-line metastatic patients, owing to the unprecedented PFS any therapy in later lines could have ever achieved.

  • Therapies for treating patients whose disease is resistant or refractory to prior HER2 treatment can potentially change the market dynamics in later-line settings.

 

Metastatic HER2-positive Breast Cancer Market Barriers

  • As the current landscape of HER2+ is already packed with old aged blockbuster therapies, companies such as Ambrx BioPharma are developing novel therapies, aiming to target ENHERTU treated patients

  • Despite the treatment with ADCs, around 20–30% of patients progress within 12 months, so there can be a significant market opportunity for therapies targeting these patients.

 

Scope of the Metastatic HER2-positive Breast Cancer Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Metastatic HER2-positive Breast Cancer Companies: Daiichi Sankyo/AstraZeneca, Roche/Chugai, Seagen, MacroGenics, Ambrx, Zymeworks/Jazz Pharmaceuticals, Taiho Oncology, GeneQuantum Healthcare, Criterium, Inc., Seagen Inc., Sichuan Baili Pharma, BioInvent International AB, and others

  • Key Metastatic HER2-positive Breast Cancer Therapies: ENHERTU (fam-trastuzumab deruxtecan-nxk), KADCYLA (ado-trastuzumab emtansine), HERCEPTIN HYLECTA, TUKYSA, MARGENZA, ARX788, Zanidatamab, TAS2940, GQ1001, Giredestrant, Alpelisib, Tucatinib, BL-M07D1, BI-1607, and others

  • Metastatic HER2-positive Breast Cancer Therapeutic Assessment: Metastatic HER2-positive Breast Cancer current marketed and Metastatic HER2-positive Breast Cancer emerging therapies

  • Metastatic HER2-positive Breast Cancer Market Dynamics: Metastatic HER2-positive Breast Cancer market drivers and Metastatic HER2-positive Breast Cancer market barriers 

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Metastatic HER2-positive Breast Cancer Unmet Needs, KOL’s views, Analyst’s views, Metastatic HER2-positive Breast Cancer Market Access and Reimbursement 

 

To know more about Metastatic HER2-positive Breast Cancer companies working in the treatment market, visit @ Metastatic HER2-positive Breast Cancer Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Metastatic HER2-positive Breast Cancer Market Report Introduction

2. Executive Summary for Metastatic HER2-positive Breast Cancer

3. SWOT analysis of Metastatic HER2-positive Breast Cancer

4. Metastatic HER2-positive Breast Cancer Patient Share (%) Overview at a Glance

5. Metastatic HER2-positive Breast Cancer Market Overview at a Glance

6. Metastatic HER2-positive Breast Cancer Disease Background and Overview

7. Metastatic HER2-positive Breast Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of Metastatic HER2-positive Breast Cancer 

9. Metastatic HER2-positive Breast Cancer Current Treatment and Medical Practices

10. Metastatic HER2-positive Breast Cancer Unmet Needs

11. Metastatic HER2-positive Breast Cancer Emerging Therapies

12. Metastatic HER2-positive Breast Cancer Market Outlook

13. Country-Wise Metastatic HER2-positive Breast Cancer Market Analysis (2020–2034)

14. Metastatic HER2-positive Breast Cancer Market Access and Reimbursement of Therapies

15. Metastatic HER2-positive Breast Cancer Market Drivers

16. Metastatic HER2-positive Breast Cancer Market Barriers

17.  Metastatic HER2-positive Breast Cancer Appendix

18. Metastatic HER2-positive Breast Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: neva
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Metastatic HER2-positive Breast Cancer Market Expected to Experience Major Growth by 2034, According to DelveInsight | Ambrx, Zymeworks/Jazz Pharma, Roche, Criterium, Seagen, Sichuan Baili Pharma,